KR960703591A - 신경변성 질병에서 플로피르틴의 일차적 및 이차적 신경보호 효과(The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases) - Google Patents

신경변성 질병에서 플로피르틴의 일차적 및 이차적 신경보호 효과(The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases) Download PDF

Info

Publication number
KR960703591A
KR960703591A KR1019960700753A KR19960700753A KR960703591A KR 960703591 A KR960703591 A KR 960703591A KR 1019960700753 A KR1019960700753 A KR 1019960700753A KR 19960700753 A KR19960700753 A KR 19960700753A KR 960703591 A KR960703591 A KR 960703591A
Authority
KR
South Korea
Prior art keywords
flupyritin
medicament
manufacture
active substance
treatment
Prior art date
Application number
KR1019960700753A
Other languages
English (en)
Other versions
KR100341952B1 (ko
Inventor
슈바르츠 미하엘
페르간데 가브리엘라
엥겔 위르겐
닉켈 베른트
울리히 하인츠
스첼레니 슈테판
Original Assignee
라이너 스크로츠키 · 라이너 곰베르트
아스타 메디카 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라이너 스크로츠키 · 라이너 곰베르트, 아스타 메디카 아크티엔게젤샤프트 filed Critical 라이너 스크로츠키 · 라이너 곰베르트
Publication of KR960703591A publication Critical patent/KR960703591A/ko
Application granted granted Critical
Publication of KR100341952B1 publication Critical patent/KR100341952B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Confectionery (AREA)
  • Medicinal Preparation (AREA)

Abstract

플루피르틴의 NMDA 길항효과는 뇌허혈증, 신경변성 장애, 외상성 뇌 및 골수 손상, 간질 발작 및 기타 질환의 치료를 위한 약제의 제조를 가능케 한다.

Description

신경변성 질병에서 플루피르틴의 일차적 및 이차적 신경보호 효과(The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 뇌 허혈증의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  2. 신경변성 질병의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  3. 간질 발작의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  4. 파킨슨씨 질병의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  5. 알츠하이머 질병의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  6. 헌팅톤 무도병의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  7. 다발성 경화증의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  8. 근위축성측색경화증의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  9. 감염-유발성 신경변성 장애의 퇴치를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  10. 대사-독성 신경변성 장애의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  11. 망막의 변성 및 허혈성 장애의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  12. 외상-유도된 뇌 및 골수 손상의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  13. 뇌 과흥분성 증후군의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  14. 말초 신경계 변성증후군의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  15. 신경이완 진통을 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
  16. 파킨슨씨 질병의 치료를 위한 플루피르틴 및 L-도파 및 도파민으로부터의 배합 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960700753A 1993-08-17 1994-08-10 신경퇴행성질환에서플로피르틴의일차적및이차적신경보호효과 KR100341952B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4327516A DE4327516A1 (de) 1993-08-17 1993-08-17 Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
DEP4327516.8 1993-08-17

Publications (2)

Publication Number Publication Date
KR960703591A true KR960703591A (ko) 1996-08-31
KR100341952B1 KR100341952B1 (ko) 2003-04-11

Family

ID=6495312

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960700753A KR100341952B1 (ko) 1993-08-17 1994-08-10 신경퇴행성질환에서플로피르틴의일차적및이차적신경보호효과

Country Status (27)

Country Link
US (1) US5721258A (ko)
EP (1) EP0716602B1 (ko)
JP (1) JPH09501664A (ko)
KR (1) KR100341952B1 (ko)
CN (1) CN1086291C (ko)
AT (1) ATE210442T1 (ko)
AU (1) AU694447B2 (ko)
BG (1) BG62430B1 (ko)
BR (1) BR9407293A (ko)
CA (1) CA2169718C (ko)
CZ (1) CZ289040B6 (ko)
DE (2) DE4327516A1 (ko)
DK (1) DK0716602T3 (ko)
EE (1) EE03204B1 (ko)
ES (1) ES2168309T3 (ko)
HR (1) HRP940464A2 (ko)
HU (1) HU227765B1 (ko)
IL (1) IL110681A (ko)
NO (1) NO309842B1 (ko)
NZ (1) NZ273292A (ko)
PT (1) PT716602E (ko)
RU (1) RU2166318C2 (ko)
SK (1) SK283330B6 (ko)
UA (1) UA43351C2 (ko)
WO (1) WO1995005175A1 (ko)
YU (1) YU49215B (ko)
ZA (1) ZA946176B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
ES2235368T3 (es) * 1997-10-27 2005-07-01 Sumitomo Pharmaceuticals Company, Limited Derivados de amida para tratar alteraciones neurodegenerativas de la retina.
AU1359801A (en) * 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
AU1353901A (en) * 1999-12-01 2001-06-12 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
CN1917876A (zh) * 2003-12-16 2007-02-21 Cns生物有限公司 方法和组合物
WO2006065204A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Substituted aminopyridines and uses thereof
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20060258708A1 (en) * 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
EP3027188A4 (en) * 2013-07-31 2017-03-01 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and flupirtine
WO2019014547A1 (en) * 2017-07-14 2019-01-17 Texas Tech University System FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481205A (en) * 1980-09-13 1984-11-06 Degussa Aktiengesellschaft 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate
DE3369315D1 (en) * 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3337593A1 (de) * 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
NO860825L (no) * 1985-03-23 1986-09-24 Degussa Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin.
IN172468B (ko) * 1990-07-14 1993-08-14 Asta Medica Ag

Also Published As

Publication number Publication date
RU2166318C2 (ru) 2001-05-10
NZ273292A (en) 1999-09-29
CN1129399A (zh) 1996-08-21
HUT75650A (en) 1997-05-28
DE4327516A1 (de) 1995-02-23
CA2169718A1 (en) 1995-02-23
EE03204B1 (et) 1999-08-16
BG62430B1 (bg) 1999-11-30
BG100356A (bg) 1996-07-31
ES2168309T3 (es) 2002-06-16
AU7652894A (en) 1995-03-14
SK283330B6 (sk) 2003-06-03
YU49215B (sh) 2004-11-25
HU227765B1 (en) 2012-02-28
ZA946176B (en) 1995-03-20
BR9407293A (pt) 1996-10-01
JPH09501664A (ja) 1997-02-18
CZ46596A3 (en) 1996-05-15
DK0716602T3 (da) 2002-03-25
SK21496A3 (en) 1997-01-08
HU9600355D0 (en) 1996-04-29
PT716602E (pt) 2002-05-31
CA2169718C (en) 2002-11-12
US5721258A (en) 1998-02-24
IL110681A (en) 1999-08-17
KR100341952B1 (ko) 2003-04-11
NO960607L (no) 1996-02-15
UA43351C2 (uk) 2001-12-17
EP0716602A1 (en) 1996-06-19
DE69429435D1 (de) 2002-01-24
IL110681A0 (en) 1994-11-11
CZ289040B6 (cs) 2001-10-17
WO1995005175A1 (en) 1995-02-23
YU51294A (sh) 1998-05-15
HRP940464A2 (en) 1997-06-30
DE69429435T2 (de) 2002-06-13
NO309842B1 (no) 2001-04-09
CN1086291C (zh) 2002-06-19
AU694447B2 (en) 1998-07-23
ATE210442T1 (de) 2001-12-15
NO960607D0 (no) 1996-02-15
EP0716602B1 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
KR960703591A (ko) 신경변성 질병에서 플로피르틴의 일차적 및 이차적 신경보호 효과(The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases)
HUP9802862A2 (hu) (1S,2S)-1-(4-hydroxi-fenil)-2-(4-hidroxi-4-fenil-1-piperidinil)-1-propanol-metánszulfonát-trihidrát, és ezt a vegyületet tartalmazó a központi idegrendszeri rendellenességek kezelésére alkalmas gyógyászati készítmények
GEP20033027B (en) Use of Substituted Benzopyran Analogs for Treatment of Inflammation
PT1040830E (pt) Medicamento para doencas neurodegenerativas
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
HUP9904525A2 (hu) S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények
MX9207495A (es) Compuestos de tetrahidroisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AU3632497A (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
WO2001041768A3 (en) Use of hymenialdisine or derivatives thereof in the manufacture of medicaments
BR9907953A (pt) Inibidores de transporte de glicina
RU96105707A (ru) Лекарственное средство для лечения дегенеративных заболеваний нервной системы
AR020762A1 (es) El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas
ECSP034518A (es) Nuevos retinoides para el tratamiento de enfisema
BR0210650A (pt) Tablete, e, uso do mesmo
ZA912652B (en) Use of n-alkylated 1,4-dihydropyridinedicarboxylic acid esters as medicaments,new compounds and processes for their preparation
DE69725549D1 (de) Isochinolderivate
AR066455A2 (es) Uso de compuestos n-metil-n-[(1r)-1-fenil-2-(3r)-3-hidroxipirrolidin -1-il-=-etil]-2,2-difenilacetamida para producir un medicamento para el tratamiento de emfermedades intestinales no inflamatorias
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
YU21096A (sh) Benzamidska jedinjenja, postupci dobijanja i farmaceutski preparati koji sadrže ova benzamidska jedinjenja
WO2004082699A3 (de) Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischämie und/oder schädel/hirntrauma
BRPI0413101A (pt) compostos de sulfonamida derivado de benzoxazinona, sua preparação e uso como medicamentos
RU97104062A (ru) Применение селегилина для лечения эпилептических заболеваний
ES2140544T3 (es) Utilizacion de efaroxan y de sus derivados para la fabricacion de medicamentos destinados al tratamiento de las enfermedades neurodegenerativas.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
N231 Notification of change of applicant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130530

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20140530

Year of fee payment: 13